undamentalytics Newsletter
Sign in

Kyntra BIO, Inc. revenue

Kyntra BIO, Inc.'s revenue was $6.4m in fiscal 2025, down 78.3% on the year before. Since fiscal 2013 ($102m) it has grown at a compound -20.6% a year. Over the last twelve months it was $4.6m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue102138181183131213257176235141473065
Growth on the year before—+34.7%+31.4%+1.3%−28.5%+62.6%+20.5%−31.3%+33.5%−40.2%−66.7%−36.7%−78.3%—
Gross profit——————255167222120431460
Gross margin——————99.6%95.0%94.5%85.6%91.5%47.5%91.4%6.3%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Drug Product Revenue $5.8M 90.8% ▼ 78.9%
Development and Other Revenue $592,000 9.2% ▼ 69.6%
Geography
Region Revenue Share YoY
Europe $5.6M 87.6% ▼ 10.0%
Japan $797,000 12.4% —
United States $0 0.0% ▼ 100.0%
China $0 0.0% ▼ 100.0%

From Kyntra BIO, Inc.'s 10-K filed March 16, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Kyntra BIO, Inc. $4.6m -37.1% -67.2%
Ocugen, Inc. $4.6m -3.7% 26.3%
Entrada Therapeutics, Inc. $4.7m -94.1% —
Bolt Biotherapeutics, Inc. $4.7m 12.8% -11.5%
Ensysce Biosciences, Inc. $4.5m -39.3% 14.6%
Rani Therapeutics Holdings, Inc. $4.9m 306.4% —

Compare with peers

Head to head: KYNB vs OCGNKYNB vs TRDABOLT vs KYNB

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Kyntra BIO, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Kyntra BIO, Inc.